706 related articles for article (PubMed ID: 17848631)
21. Eldecalcitol Causes FGF23 Resistance for Pi Reabsorption and Improves Rachitic Bone Phenotypes in the Male Hyp Mouse.
Kaneko I; Segawa H; Ikuta K; Hanazaki A; Fujii T; Tatsumi S; Kido S; Hasegawa T; Amizuka N; Saito H; Miyamoto KI
Endocrinology; 2018 Jul; 159(7):2741-2758. PubMed ID: 29878089
[TBL] [Abstract][Full Text] [Related]
22. FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6.
Uchihashi K; Nakatani T; Goetz R; Mohammadi M; He X; Razzaque MS
Contrib Nephrol; 2013; 180():124-37. PubMed ID: 23652555
[TBL] [Abstract][Full Text] [Related]
23. Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice.
Carpenter KA; Davison R; Shakthivel S; Anderson KD; Ko FC; Ross RD
Bone; 2022 Jan; 154():116201. PubMed ID: 34537437
[TBL] [Abstract][Full Text] [Related]
24. Novel regulators of Fgf23 expression and mineralization in Hyp bone.
Liu S; Tang W; Fang J; Ren J; Li H; Xiao Z; Quarles LD
Mol Endocrinol; 2009 Sep; 23(9):1505-18. PubMed ID: 19556340
[TBL] [Abstract][Full Text] [Related]
25. The wrickkened pathways of FGF23, MEPE and PHEX.
Rowe PS
Crit Rev Oral Biol Med; 2004 Sep; 15(5):264-81. PubMed ID: 15470265
[TBL] [Abstract][Full Text] [Related]
26. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.
Martin A; David V; Laurence JS; Schwarz PM; Lafer EM; Hedge AM; Rowe PS
Endocrinology; 2008 Apr; 149(4):1757-72. PubMed ID: 18162525
[TBL] [Abstract][Full Text] [Related]
27. Genetic Ablation of Osteopontin in Osteomalacic Hyp Mice Partially Rescues the Deficient Mineralization Without Correcting Hypophosphatemia.
Hoac B; Østergaard M; Wittig NK; Boukpessi T; Buss DJ; Chaussain C; Birkedal H; Murshed M; McKee MD
J Bone Miner Res; 2020 Oct; 35(10):2032-2048. PubMed ID: 32501585
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype.
Liu S; Guo R; Tu Q; Quarles LD
J Biol Chem; 2002 Feb; 277(5):3686-97. PubMed ID: 11713245
[TBL] [Abstract][Full Text] [Related]
29. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.
Liu S; Guo R; Simpson LG; Xiao ZS; Burnham CE; Quarles LD
J Biol Chem; 2003 Sep; 278(39):37419-26. PubMed ID: 12874285
[TBL] [Abstract][Full Text] [Related]
30. Phex mutation causes overexpression of FGF23 in teeth.
Onishi T; Umemura S; Shintani S; Ooshima T
Arch Oral Biol; 2008 Feb; 53(2):99-104. PubMed ID: 17942069
[TBL] [Abstract][Full Text] [Related]
31. Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia.
Leifheit-Nestler M; Kucka J; Yoshizawa E; Behets G; D'Haese P; Bergen C; Meier M; Fischer DC; Haffner D
Bone; 2017 Oct; 103():224-232. PubMed ID: 28728941
[TBL] [Abstract][Full Text] [Related]
32. Tissue-specific mineralization defects in the periodontium of the Hyp mouse model of X-linked hypophosphatemia.
Coyac BR; Falgayrac G; Baroukh B; Slimani L; Sadoine J; Penel G; Biosse-Duplan M; Schinke T; Linglart A; McKee MD; Chaussain C; Bardet C
Bone; 2017 Oct; 103():334-346. PubMed ID: 28764922
[TBL] [Abstract][Full Text] [Related]
33. Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia.
Feng JQ; Clinkenbeard EL; Yuan B; White KE; Drezner MK
Bone; 2013 Jun; 54(2):213-21. PubMed ID: 23403405
[TBL] [Abstract][Full Text] [Related]
34. Contributions of increased osteopontin and hypophosphatemia to dentoalveolar defects in osteomalacic Hyp mice.
Mohamed FF; Hoac B; Phanrungsuwan A; Tan MH; Giovani PA; Ghiba S; Murshed M; Foster BL; McKee MD
Bone; 2023 Nov; 176():116886. PubMed ID: 37634682
[TBL] [Abstract][Full Text] [Related]
35. FGF23 and its role in X-linked hypophosphatemia-related morbidity.
Beck-Nielsen SS; Mughal Z; Haffner D; Nilsson O; Levtchenko E; Ariceta G; de Lucas Collantes C; Schnabel D; Jandhyala R; Mäkitie O
Orphanet J Rare Dis; 2019 Feb; 14(1):58. PubMed ID: 30808384
[TBL] [Abstract][Full Text] [Related]
36. Impaired 1,25 dihydroxyvitamin D3 action and hypophosphatemia underlie the altered lacuno-canalicular remodeling observed in the Hyp mouse model of XLH.
Yuan Y; Jagga S; Martins JS; Rana R; Pajevic PD; Liu ES
PLoS One; 2021; 16(5):e0252348. PubMed ID: 34043707
[TBL] [Abstract][Full Text] [Related]
37. Crossfibrillar mineral tessellation in normal and Hyp mouse bone as revealed by 3D FIB-SEM microscopy.
Buss DJ; Reznikov N; McKee MD
J Struct Biol; 2020 Nov; 212(2):107603. PubMed ID: 32805412
[TBL] [Abstract][Full Text] [Related]
38. Sclerostin Antibody Treatment Increases Bone Mass and Normalizes Circulating Phosphate Levels in Growing Hyp Mice.
Carpenter KA; Ross RD
J Bone Miner Res; 2020 Mar; 35(3):596-607. PubMed ID: 31743490
[TBL] [Abstract][Full Text] [Related]
39. PHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolism.
Zelenchuk LV; Hedge AM; Rowe PS
PLoS One; 2014; 9(5):e97326. PubMed ID: 24839967
[TBL] [Abstract][Full Text] [Related]
40. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
